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High prevalence of potential biases threatens
the interpretation of trials in patients with
chronic disease
Daniela Vollenweider1, Cynthia M Boyd2 and Milo A Puhan3,4*
Abstract
Background: The complexity of chronic diseases is a challenge for investigators conducting randomized trials. The
causes for this include the often difficult control for confounding, the selection of outcomes from many potentially
important outcomes, the risk of missing data with long follow-up and the detection of heterogeneity of treatment
effects. Our aim was to assess such aspects of trial design and analysis for four prevalent chronic diseases.
Methods: We included 161 randomized trials on drug and non-drug treatments for chronic obstructive pulmonary
disease, type 2 diabetes mellitus, stroke and heart failure, which were included in current Cochrane reviews. We
assessed whether these trials defined a single outcome or several primary outcomes, statistically compared baseline
characteristics to assess comparability of treatment groups, reported on between-group comparisons, and we also
assessed how they handled missing data and whether appropriate methods for subgroups effects were used.
Results: We found that only 21% of all chronic disease trials had a single primary outcome, whereas 33% reported
one or more primary outcomes. Two of the fifty-one trials that tested for statistical significance of baseline
characteristics adjusted the comparison for a characteristic that was significantly different. Of the 161 trials, 10%
reported a within-group comparison only; 17% (n = 28) of trials reported how missing data were handled (50% (n
= 14) carried forward last values, 27% (n = 8) performed a complete case analysis, 13% (n = 4) used a fixed value
imputation and 10% (n = 3) used more advanced methods); and 27% of trials performed a subgroup analysis but
only 23% of them (n = 10) reported an interaction test. Drug trials, trials published after wide adoption of the
CONSORT (CONsolidated Standards of Reporting Trials) statement (2001 or later) and trials in journals with higher
impact factors were more likely to report on some of these aspects of trial design and analysis.
Conclusion: Our survey showed that an alarmingly large proportion of chronic disease trials do not define a
primary outcome, do not use appropriate methods for subgroup analyses, or use naïve methods to handle missing
data, if at all. As a consequence, biases are likely to be introduced in many trials on widely prescribed treatments
for patients with chronic disease.
Background
Previous studies have shown that the quality of report-
ing of important aspects of randomized clinical trials
(RCTs) is often poor [1-6]. These studies have indicated
that a substantial proportion of RCTs might be at high
risk for confounding, selection and information biases
because they were not designed optimally to minimize
threats to internal validity. For example, the method of
randomization was often not reported, so that it was not
clear if the RCTs actually controlled for confounding by
correct randomization, or concealment of random
allocation was not described, which may have put the
studies at risk for selection bias. Many trial reports also
lacked details about the method of masking of patients,
treatment providers or those ascertaining the outcomes.
The introduction of CONSORT (CONsolidated Stan-
dards of Reporting Trials) improved the quality of
reporting of clinical trials, but there is still a large pro-
portion of RCTs that are of uncertain internal validity
and value for informing clinical practice [7].
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The complexity of chronic diseases represents addi-
tional challenges to investigators conducting randomized
trials. Even if a trial scores high on the standard criteria
for assessing the risk of bias (method of randomization,
concealment and masking), it may still not provide
high-quality data to answer a research question. For
example, patients with chronic diseases form heteroge-
neous study populations, so that it may be more difficult
to control for confounding. In addition, chronic disease
trials often have longer follow-up durations so that the
risk for low treatment adherence and missing data
increases, which may lead to selection bias [8]. Finally,
there is often a great variety of potential outcomes avail-
able including mortality, various clinical events, patient-
reported outcomes, and surrogate outcomes. As a con-
sequence, some RCTs may not explicitly define a pri-
mary outcome, even though this is important to
calculate the required sample size and to avoid selective
outcome reporting [9]. In addition, although not choos-
ing a primary outcome does not directly lead to biased
results, it may lead to study designs that do not opti-
mally control for confounding for some outcomes. For
example, if 5-year mortality is the primary outcome in a
trial, the confounders that should be taken into consid-
eration for the study design are likely to be different
from a trial where quality of life after 1 year is the pri-
mary outcome [9,10]. Restriction of the study population
and pre-stratification, two powerful tools to control for
confounding, would be designed differently depending
on whether the primary outcome is 5-year mortality or
1-year quality of life. Finally, treatment effects may vary
across heterogeneous study populations, and subgroup
analyses should be appropriately designed, conducted
and reported to avoid spurious findings [11,12].
We were interested in the proportion of trials that are
at risk of biases caused by these aspects of trial design
and analysis. To evaluate such sources of bias, which t
have received less attention in studies on prevalent and
high-burden chronic diseases, our aim was to assess
these aspects in trials that investigated the effects of
widely prescribed drug and non-drug treatments.
Methods
Study design
We conducted a survey of trial reports on widely pre-
scribed drug and non-drug trials in patients with four
common chronic diseases: chronic obstructive pulmon-
ary disease (COPD), heart failure, stroke and type 2 dia-
betes mellitus (T2DM).
Study selection
We decided to focus on diseases associated with high
morbidity and mortality for patients and with significant
healthcare expenditure [13-15]. We hypothesized that
methodological deficiencies of trials that provided evi-
dence on treatments for such diseases could bias effect
estimates and, therefore, clinical practice. We focused
on widely prescribed drug and non-drug therapies for
which we wanted to have comprehensive sets of trials as
identified by systematic reviews, each addressing a speci-
fic research question. Therefore, we based the selection
of RCTs on 11 Cochrane Reviews that systematically
identified and summarized RCTs on the effectiveness of
diuretics, metformin, anticoagulants, long-acting b ago-
nists alone or in combination with inhaled corticoster-
oids, lipid-lowering agents and the non-drug
interventions of exercise and diet for each of the four
diseases [16-26]. We included all available reviews in
these fields except for the stroke literature, where sev-
eral other reviews about other drug and non-drug treat-
ments exist. The search strategy and eligibility criteria
have been described in these Cochrane reviews. We
retrieved the main reports of included RCTs, and also
retrieved additional papers that described the methods
of these trials. We assessed only the reporting of trials
and not their conduct because the protocols or internal
reports were not available to us. We did not consider
abstracts and unpublished data used in the Cochrane
reviews because they could not provide the level of
detail that we needed, and we excluded 22 trials (out of
183) for that reason. The bibliography of excluded trials
is available on request.
Data extraction
Before systematically extracting data from each trial, we
developed a codebook that provided a detailed descrip-
tion of the information to be extracted and how to
score it. We pilot tested the data-extraction forms and
the codebook on a random sample of 10 articles. All
data were then extracted by one reviewer into an online
database, and checked by at least one other reviewer.
Disagreements were discussed and resolved.
Definition of primary outcome
We recorded whether there were one or more clearly
defined primary outcomes. Beside guiding interpretation
[27] and sample size calculations, defining a primary
outcome is important for designing a trial that mini-
mizes confounding indirectly by the use of restriction
(exclusion criteria that eliminate some levels of charac-
teristics that may act as confounders), pre-stratification
for prognostically important variables, and the collection
of data for potential statistical adjustment. Confounders
can be profoundly different depending on the primary
outcome (for example, mortality versus quality of life)
[9]. Possible answer keys for data extraction included
‘Yes, clearly defined’ if the authors made an explicit dis-
tinction between the primary and secondary outcomes,
and ‘No’ if they did not make distinction between
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primary and secondary outcomes. For those papers that
did describe a primary outcome, we also recorded
whether the primary outcome was only one measure
(for example, percentage of forced expiratory volume in
one second predicted at 1 year of follow-up) or whether
multiple measures were considered as primary outcome
(for example, different individual measures, or one mea-
sure at different time points at which treatment effect
may differ).
Between- and within-group comparisons
We recorded whether or not there were only within-
group comparisons reported and no reporting of
between-group comparisons (’Yes’, ‘No’ or ‘Unclear’).
Within-group comparisons are a comparison of baseline
and follow-up measurements within each treatment
group, rather than an effect estimate for a randomized
comparison between groups. Based on a within-group
comparison, it is not possible to tell whether a change
was caused by the intervention or by some other factor.
Comparison of baseline characteristics and decisions to
adjust for baseline imbalances
We recorded whether a between-group comparison of
baseline characteristics was made to assess significant
differences (for example, P values in Table 1). This is
not a particularly useful comparison, because it tests the
null hypothesis that treatment groups are not different,
even though we know that through randomization the
null hypothesis is true [28-30]. Even more importantly,
such testing may misguide the statistical analysis as
investigators may inappropriately use these differences
to over- or under-adjust for potential confounders, even
though significant differences at baseline occur by
chance in 5% of the variables tested. Indeed, confound-
ing of observed treatment effects may result if certain
characteristics are not well balanced and are thus asso-
ciated with treatment exposure, or if they influence the
outcome but are not a result of treatment exposure
(intermediates). However, the decision for or against
considering a variable to be a confounder should not be
made based on testing for statistical significance but
rather on prior evidence and/or biological rationale.
Therefore, we distinguished between ‘Yes, reporting of P
values and/or the term statistical significance’, ‘Yes, sig-
nificant’ (which may refer to a statistical analysis but
also to a clinically relevant difference), ‘No’ and ‘Does
not apply’ in the case of crossover studies. For those
papers in which the investigators tested for baseline dif-
ferences, we assessed what actions were taken as a con-
sequence of testing. We recorded if the authors adjusted
for a significant difference in a baseline characteristic or
mentioned it in the Discussion section. If they did not
find any significant differences, we assessed if they
adjusted for large-magnitude differences in baseline
characteristics irrespective of significant tests, or
adjusted for a potential confounder unrelated to baseline
characteristics.
Missing data
Missing data occur in almost any study for some out-
comes or covariates [10]. We were interested in how
chronic disease trials handled missing data because of
the potential bias on treatment effects. If data are miss-
ing at random and non-differentially in different treat-
ment groups, effect estimates are, in the best case, still
valid although less precise. However, if patients drop
out of a trial (for example, because of adverse effects)
and do not provide outcome data, a selection bias may
occur if these patients are dropped from the analyses or
censored [8]. In addition, if data for confounders are
missing, the statistical adjustment for potential con-
founding is compromised. We assessed whether or not
the approach to the handling of missing data was
reported (’Yes’, ‘No’ and ‘Unclear’) and recorded the cor-
responding methods (for example, last value carried for-
ward, imputation of fixed values such as mean or
multiple imputation). If the authors reported the missing
data, but dropped those participants from analysis, we
recorded it as a complete case analysis.
Intention-to-treat analysis
We also assessed whether or not an intention-to-treat
(ITT) analysis was reported. An ITT analysis is an ana-
lysis based on the initial treatment intent, not on the
treatment eventually administered. Changing a patient
from their assigned treatment arm to another arm dur-
ing the trial and/or dropping some patients from the
analysis also leads to selection bias. We considered an
analysis to be ITT if the authors explicitly described the
analysis as such, or if the numbers of patients included
in the analysis corresponded exactly to those rando-
mized to the respective treatment groups [31].
Reporting of point estimates and measures of precision
To interpret treatment effects, trial reports should
include point estimates, confidence intervals (CIs) and P
values. P values alone do not suffice to interpret the
results of trials because they are influenced by both
sample size and effect size. We registered whether trial
reports included P value only, 95% CI only, both, or
neither.
Subgroup analyses to investigate heterogeneity of
treatment effects
Finally, we assessed how often and in what way sub-
group analyses were performed, using recently described
criteria [11,12]. We defined a subgroup analysis as the
analysis of an effect that varied (or not) depending on
different levels of a variable measured before randomiza-
tion. We assessed whether this occurred by using ‘Yes’
and ‘No’. For those trials that did report one or more
subgroup effects, we recorded whether just one, a small
number (two to five) of or a large number (more than
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five) of subgroup effects were reported. We recorded the
proportion of trials using an interaction term to com-
pare treatment effects across various other factors and
whether the interaction terms were statistically indepen-
dent of other subgroup effects. In addition, we assessed
whether or not subgroup effects were consistent across
closely related outcomes. We also assessed if the authors
had specified a hypothesis for why a subgroup effect
could be present, based on evidence from the literature
or biological plausibility, and whether they pre-specified
the direction of the subgroup effect.
Statistical analysis
We used descriptive statistics to summarize our findings
across the entire set of trials, and stratified by disease,
type of treatment (drug versus non-drug), time of publi-
cation (before and after 2001, when many journals
adopted the CONSORT statement) and the impact fac-
tor of the journal in which the reports were published
(per unit increase of the 2009 impact factor), which we
used as an indirect measure for the overall quality of a
trial. We used simple and multiple logistic regression
analysis to detect the association of the sources of bias
we assessed with type of treatment, time of publication
and the impact factor of the journal. For analyses with
time of publication as a covariate, we restricted the ana-
lysis to trials published in or after 1990, because initia-
tives to improve trial reporting, such as CONSORT, did
not start before 1990. All analyses were conducted with
Stata for Windows (version 10.1; Stata Corp., College
Station, TX, USA).
Results
Based on the 183 studies included in 11 Cochrane
reviews, we were able to include 161 RCTs published
between 1966 and 2009. The distribution of the type of
diseases evaluated in the reports was as follows: COPD
(n = 49), heart failure (n = 31), T2DM (n = 48), stroke
(n = 33). Nearly half (43%; n = 70) were drug trials,
which assessed long-acting b agonists (n = 21), lipid-
lowering agents (n = 7), metformin (n = 26), diuretics (n
= 12) and oral anticoagulants (n = 4), while the remain-
der (57%; n = 91) assessed were non-drug interventions
such as rehabilitation (n = 69) and exercise and/or diet
(n = 22).
Sources of bias, overall and stratified for type of disease
and type of intervention
Testing for statistical significance of baseline characteris-
tics was not reported by 68% (n = 110) of all trials
(Table 1). Of the 51 papers that did reported testing for
statistical significance of baseline characteristics, 38% (n
= 20) found at least one characteristic with a significant
difference. Of these twenty papers, two (10%) had
results adjusted for the characteristic; four (20%) had
the difference in baseline characteristics discussed in the
Discussion section, and one (5%) (in which no signifi-
cant difference in baseline characteristics was found)
had the results adjusted for a characteristic measured at
baseline because the difference between groups was con-
sidered to be large. A between-group comparison was
reported in 90% of the 161 trials (n = 145), while 10%
reported only a within-group analysis. An ITT analysis
was reported in 42% (67 trials).
Only 17% (n = 28) of groups reported on how missing
data were handled: 50% (n = 14) carried forward last
values, 27% (n = 8) performed a complete case analysis,
13% (n = 4) used a fixed value imputation and 10% (n =
3) used more advanced methods, such as a regression
model that also took into account patients with missing
data, and a stratified imputation (one trial used two
methods of handling missing data). Only 24% (n = 40)
reported both P value and 95% CI. One or more pri-
mary outcomes were defined in 33% of trials (n = 53)
but only 21% (n = 34) of the trials had a single primary
outcome.
For three of the sources of bias we evaluated, the trials
scored similarly across disease areas (Figure 1). For all
four diseases, a single primary outcome was clearly
defined in a similar proportion of trials, P value and
95% CI were reported in approximately 20% of trials,
and between-group comparisons were conducted in
approximately 90% of trials. Large differences between
disease areas were present for the reporting of an ITT
analysis (29 to 58% of trials), reporting on the handling
of missing data (6 to 30% of trials) and not reporting on
statistical comparisons of baseline characteristics (55 to
74% of trials). In the trials of drugs for heart failure,
only 67% (n = 8) reported a between-group comparison,
and this category of trials was also worse in terms of
other sources of bias, whereas trials of drugs for COPD
scored higher than drug trials of any other disease areas.
Association of trial quality with type of intervention, year
of publication and impact factor
Simple regression analysis (Table 2) showed that drug
trials were significantly more likely than non-drug trials
to clearly define one or more primary outcomes, to
include an ITT analysis, and to avoid testing for differ-
ences in baseline characteristics. Defining one or more
primary outcomes was significantly more likely after the
year 2001. Finally, a high impact factor was associated
with defining one or more primary outcomes, reporting
of the handling of missing data, inclusion of P values
and 95% CI, and use of an ITT analysis. In multivariate
analyses (Table 3), drug trials were still more likely than
non-drug trials to define one or more primary out-
comes, to conduct an ITT analysis, and to avoid testing
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Table 1 Reporting of aspects of trial design, conduct and analysis: Stratified by diseases and types of Intervention
Interventions All Drug COPD Heart failure Diabetes Stroke
Non-drug Drug Non-drug Drug Non-drug Drug Non-drug Drug Non-drug
Number of trials 161 70 91 20 29 12 19 26 22 12 21
Reporting of between- group comparisons, % (n) 90% (145) 90% (63) 89% (81) 100% (20) 93% (27) 67% (8) 95% (18) 92% (24) 82% (18) 92% (11) 86% (18)
Primary outcome, % (n) 33% (53) 50% (35) 20% (18) 70% (14) 7% (2) 17% (2) 21% (4) 42% (11) 36% (8) 67% (8) 19% (4)
Primary outcome is only one measure, % (n) 21% (34) 31% (22) 13% (12) 35% (7) 0% (0) 8% (1) 16% (3) 27% (7) 32% (7) 58% (7) 10% (2)
No statistical comparison of baseline characteristics, % (n) 68% (110) 79% (55) 60% (55) 85% (17) 59% (17) 83% (10) 68% (13) 73% (19) 73% (16) 75% (9) 43% (9)
Reporting of handling of missing data, % (n) 17% (28) 21% (15) 13% (12) 20% (4) 10% (3) 8% (1) 5% (1) 27% (7) 9% (2) 25% (3) 33% (7)
Intention-to-treat analysis reported, % (n) 42% (67) 53% (37) 33% (30) 70% (14)% 24% (7) 33% (4) 26% (5) 46% (12) 27% (6) 58% (7) 57% (12)
Reporting of P values and 95% CI % (n) 24% (38) 31% (22) 20% (18) 45% (9) 24% (7) 8% (1) 16% (3) 19% (5) 32% (7) 58% (7) 5% (1)
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for differences in baseline characteristics. A more recent
year of publication remained associated with defining
one or more primary outcomes and the reporting of
handling of missing data. A higher impact factor
remained strongly associated with the reporting of one
or more primary outcomes, a description of the hand-
ling of missing data, and the reporting of P values and
95% CI.
Reporting of subgroup analyses
A subgroup analysis of variables measured before rando-
mization was reported in 27% (n = 43) trials; of these,
only 23% (n = 10) reported an interaction test, whereas
77% reported either separate tests for each subgroup or
tests for one subgroup only. Of the 43 trials reporting
subgroup analyses, 81% (n = 35) reported a small num-
ber (< 5) of subgroups. In trials (n = 19) in which more
than one significant subgroup effect was reported, 21%
(n = 4) reported whether these effects were independent
from other subgroup effects (that is, if interaction terms
were still significant when other interaction terms were
in the same regression model). Of the 34 trials that
reported related outcomes, only 15% (n = 5) of trials
found a consistent direction of the subgroup effects
among closely related outcomes. Finally, of the forty-
three trials that performed a subgroup analysis, 16% (n
= 7) specified a hypothesis for a subgroup effect a priori
but only two of these trials explained the rationale of
their hypothesis by discussing prior evidence and biolo-
gical plausibility. None of the trials pre-specified the
direction of a potential subgroup effect.
Discussion
Main findings
We found in our survey of 161 chronic disease trials of
widely prescribed therapies that an alarmingly large pro-
portion of trials do not define a primary outcome, use
naive methods to handle missing data (if at all), or do
not use appropriate methods for subgroup analyses, or
they test for baseline differences between groups. These
0 10 20 30 40 50 60 70 80 90 100
Reporting of between-
group comparisons
Stroke
Heart Failure
Diabetes
COPD
Primary outcome is 
only one measure Stroke
Heart Failure
Diabetes
COPD
No statistical comparison 
of baseline characteristics
Stroke
Heart Failure
Diabetes
COPD
Intention to treat Diabetes
COPD
Reporting of missing 
data
Stroke
Heart Failure
Diabetes
COPD
- -
analysis Stroke
Heart Failure
Reporting of 95% CI 
and p-values Heart Failure
Diabetes
COPD
0 10 20 30 40 50 60 70 80 90 100
Percentage of trials 
Stroke
Figure 1 Reporting of aspects of trial design, conduct and analysis. The dot plot shows the proportion of trials in patients with chronic
obstructive pulmonary disease (COPD) (49 trials), diabetes (48 trials), heart failure (31 trials) and stroke (33 trials) that reported on important
aspects of trial design, conduct and analysis.
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findings indicate that a substantial proportion of trials
are at risk for confounding or selection bias, or for not
reporting the results in a way that would support clini-
cal decision-making. Trials published after wide adop-
tion of the CONSORT statement by journals in 2001
were significantly better in some aspects of trial quality,
but factors other than the CONSORT statement may
also have contributed to this improvement. Trials pub-
lished in high-impact journals were significantly better
at reporting both P values and 95% CI, and in specifying
a primary outcome.
In all disease areas, most trials reported between-
group comparisons, which is a promising sign that the
problem of reporting within-group comparisons is not
very prevalent in the literature on chronic disease. A
greater problem is the still prevalent practice of report-
ing statistical comparisons of baseline characteristics,
particularly in the stroke literature. It may be that in
stroke-research investigators face a particular challenge
of a heterogeneous patient population in which simple
randomization or smaller trials may not yield balanced
groups. However, statistical testing for differences in
baseline characteristics does not provide appropriate
guidance for adjustment for confounders. For the three
aspects of definition of a primary outcome, handling of
missing data and reporting of P values and 95% CI, the
proportion of trials reporting these was low.
An interesting finding was that one-third of trials that
specified a primary outcome actually defined more than
one primary outcome. Many authors would argue
against this practice because having several primary out-
comes may lead to difficulties in interpretation or even
selective outcome reporting. To prevent this would
require a sample size that provides sufficient power for
all primary outcomes. In addition, it may be difficult to
choose means to control for confounding because the
confounders could be different for different outcomes.
However, the practice of multiple primary outcomes is
currently supported by the European Medicines Agency
(EMA), which requires industry trials on COPD to show
Table 2 Simple logistic regression to compare aspects of trial design, conduct and analysis by types of intervention,
time before and after CONSORT (2001) and impact of journal
Drug,
% (n)
Non-
drug,
% (n)
Odds ratio (95%
CI)
(P-value)
From
2001,
% (n)
Before
2001,% (n)
Odds ratio (95%
CI)
(P value)
Odds ratio (95% CI) (P
value) per increase of 1
unit in impact factor
Number of trials 70 91 - 72 67 - 161
Reporting of between- group
comparisons
90% (63) 90% (82) 0.98 (0.35 to
2.80) (0.98)
96%
(69)
91% (61) 2.26 (0.54 to
9.44) (0.26)
1.03 (0.97 to 1.11) (0.32)
Primary outcome reported 47% (33) 20% (18) 4.06 (2.02 to
8.14) (< 0.001)
53%
(38)
21% (14) 4.23 (2.00 to
8.95) (< 0.001)
1.05 (1.02 to 1.09) (0.001)
Primary outcome is only one
measure
31% (22) 13% (12) 3.02 (1.37 to
6.65) (0.006)
36%
(26)
12% (8) 4.17 (1.73 to
10.06) (0.001)
1.05 (1.02 to 1.08) (0.002)
No statistical comparison of
baseline characteristics
79% (55) 60% (55) 2.40 (1.18 to
4.88) (0.015)
68%
(49)
70% (47) 0.91 (0.44 to
1.86) (0.79)
1.03 (1.00 to 1.08) (0.089)
Reporting of handling of
missing data
21% (15) 14% (13) 1.63 (0.72 to
3.71) (0.24)
26%
(19)
13% (9) 2.31 (0.96 to
5.55) (0.06)
1.04 (1.01 to 1.07) (0.021)
Intention-to-treat analysis
reported
53% (37) 33% (30) 2.28 (1.20 to
4.33) (0.01)
53%
(38)
39% (26) 1.76 (0.90 to
3.46) (0.10)
1.03 (1.00 to 1.06) (0.047)
Reporting of P values and 9% CI 30% (21) 19% (17) 1.87 (0.89 to
3.89) (0.10)
32%
(23)
22% (15) 1.63 (0.76 to
3.47) (0.21)
1.07 (1.04 to 1.11) (< 0.001)
Table 3 Multiple logistic regression to assess the associations of types of intervention, time before and after CONSORT
and impact of journal with aspects of trial design, conduct and analysis
Drug versus non-drug From 2001 versus before
2001
Per increase of 1 unit in impact
factor
Reporting of between-group comparisons 2.39 (0.46 to 12.50) (0.30) 2.73 (0.63 to 11.90) (0.18) 1.19 (0.95 to 1.49) (0.14)
Primary outcome reported 8.15 (3.16 to 21.03) (<
0.001)
8.46 (3.18 to 22.49) (< 0.001) 1.06 (1.01 to 1.11) (0.010)
Primary outcome is only one measure 4.19 (1.68 to 10.46) (0.002) 5.81 (2.17 to 15.59) (< 0.001) 1.04 (1.01 to 1.08) (0.018)
No statistical comparison of baseline
characteristics
2.48 (1.11 to 5.56) (0.027) 0.97 (0.46 to 2.03) (0.93) 1.0 2 (0.98 to 1.06) (0.30)
Reporting of handling of missing data 1.79 (0.74 to 4.32) (0.20) 2.47 (1.00 to 6.10) (0.049) 1.03 (1.00 to 1.06) (0.07)
Intention-to-treat analysis reported 2.88 (1.39 to 5.99) (0.005) 2.02 (0.99 to 4.15) (0.055) 1.03 (0.99 to 1.06) (0.11)
Reporting of P values and 95% CI (n) 1.85 (0.81 to 4.24) (0.15) 1.83 (0.79 to 4.22) (0.16) 1.07 (1.03 to 1.12) (< 0.001)
Data are odds ratios (95% CI) (P value)
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efficacy for two co-primary outcomes [32]. Specifying
co-primary outcomes may still be better than specifying
none, but it will be interesting to see whether difficulties
in interpretation of trials arise once trials following the
EMA guidance are published.
Results in the context of the literature
Several reviews have focused on the conventional
aspects of trial quality, such as reporting of methods of
masking, randomization or concealment of random allo-
cation [2-4,6], but we are not aware of any other reviews
in the area of chronic diseases that have analyzed all of
the aspects of trial design and analysis that are particu-
larly important for chronic disease trials [29]. A review
of endocrinology trials that were published in 2005 and
2006 found that 34% of trials reported a clearly defined
primary outcome, a result similar to what we found for
the diabetes trials [33]. Another review focused on sub-
group reporting, and found a similar extent of reporting
of interaction tests as we did [34]. Bath et al. reviewed
the stroke literature, and assessed conventional aspects
of trial quality [35], and did not find publication in
high-impact journals to be strongly associated with trial
quality. Finally, a survey of more than 300 trials in
COPD found, as we did, that adoption of the CON-
SORT statement improved the reporting of conventional
aspects of trial design [1]. Overall, the results we found
for each of the four clinical domains are similar to those
of previous studies that were restricted to one disease
area. This is important because it shows that our selec-
tion of trials, based on existing Cochrane reviews, seems
to be a good representation of the trials in COPD, dia-
betes, heart failure and stroke, and thus allow for com-
parisons across these four disease areas.
Strengths and limitations
The strengths of this study are the number and the
diversity of the included trials, thus providing a broad
overview of chronic disease trials of widely prescribed
therapies. Hence, the quality of these trials is of great
relevance to inform medical decision-making. Our sur-
vey goes beyond conventional aspects of internal valid-
ity. We believe that the aspects we assessed here, which
are all referred to in the CONSORT statement, are clo-
sely related to the internal validity and interpretability of
chronic disease trials [36,37]. We paid great attention to
a rigorous data-extraction process and to standardized
data collection in a secured database. A limitation of
our study is that we did not assess whether the aspects
of study design and reporting assessed in this paper
affected the effect estimates. However, the relationship
between reported aspects of trial quality and effect esti-
mates is very challenging, and would require a different
approach and study [6]. Finally, because only 17% of
trials reported on the handling of missing data, we had
only limited ability to investigate how the investigators
handled missing data. Future studies should focus on
the reporting of missing data and explore, based on
more data, what methods (none, naive or advanced
methods) investigators use to deal with this.
Implications of our results for the design, reporting and
interpretation of chronic disease trials
Our results show that current trials in patients with
chronic disease are not optimally designed, conducted,
analyzed and reported, and as a consequence, readers
may often be left with uncertainty about the validity of
the trials’ findings. What can be done to improve the
quality of trials in patients with chronic disease? Investi-
gators carrying out clinical trials may not always know
why certain features of trial design are important. We
believe that a way forward would be not only to inform
investigators what ought to be carried out and reported
(as is laid out in the CONSORT statement) but also to
have a better explanation of how the features of trial
design help reduce bias. A clinical trial is no different
from any epidemiological study; the primary concern
should be minimization of confounding, selection bias
and measurement error that lead to information bias.
There seems to be too little awareness of the problems
of selection bias and missing data. A number of studies
have found that many trials do not report or use inap-
propriate methods to conceal the random allocation
[38]. Similarly, we found that many trials do not report
on the handling of missing data and ways to deal with
it. It is difficult to quantify the bias that results from dif-
ferent ways of (not) dealing with missing data because
individual patient data from many different trials would
be needed to investigate this. To improve reporting on
missing data, editors and reviewers should require inves-
tigators to follow the CONSORT statement and report
on their efforts to minimize bias from missing data and
to report when they were unable to do so explicitly. The
CONSORT statement includes all of the aspects of trial
quality discussed here, and several studies, including
ours, have shown that it was associated with the quality
of reporting at least to some extent [1].
Conclusion
From our survey of 161 randomized trials, we found
that an alarmingly large proportion of chronic disease
trials do not define a primary outcome, do not use
appropriate methods for subgroup analyses, or use naive
methods to handle missing data, if at all. As a conse-
quence, biases are likely to be introduced in many trials
on widely prescribed treatments in patients with chronic
disease, and thus clinical decision-making based on
these trials often may not be well informed. In addition
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to recommending wider adoption of the CONSORT
statement, we suggest that investigators see clinical trials
as any epidemiologic study in which particular attention
needs to be paid to an optimum control for biases in
accordance with established epidemiologic methods.
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